Understanding the molecular interactions between fibrinogen and GPIIb-IIIa provides the mechanistic basis for how RGD-containing peptides inhibit platelet aggregation and arterial thrombosis.
No takes yet. Share an insight, caveat, or question.
May inform GPIIb-IIIa inhibitor design; leaves open clinical validation in thrombosis.
Joel Bennett (2001) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: